MMA loans

BiondVax will host a webinar in Hebrew for analysts and investors on April 6

JERUSALEM, April 5, 2022 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that the company will host a webinar tomorrow to analysts and investors, April 6andin Hebrew.

CEO Amir Reichman will discuss the latest business updates, including:

  • The collaboration for the development of the nanoscale antibody (NanoAb) pipeline with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), Germany
  • In-house preparations for the manufacture of NanoAbs at the company’s GMP biologics manufacturing facility in Jerusalem
  • Negotiations regarding the restructuring of the European Investment Bank loan ensuring continued long-term support for BiondVax
  • FY21 financial results

Time permitting, the webinar will be open to questions and answers.

Webinar details

Recording of yesterday’s English webinar

Tomorrow’s Hebrew webinar complements yesterday’s English webinar, which also featured Professor Dr. Matthias Dobbelstein briefly discussing recent NanoAb research results. A recording of yesterday’s English webinar is available at (registration required) or on the BiondVax website.

About BiondVax

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and marketing innovative products for the prevention and treatment of infectious and other diseases. Since its inception, the company has completed eight clinical trials, including a phase 3 trial in seven countries and 12,400 participants of its candidate vaccine and has built a state-of-the-art manufacturing facility for biopharmaceuticals. With highly experienced leadership in the pharmaceutical industry, BiondVax aims to develop a pipeline of diverse and commercially viable products and platforms, starting with an innovative nanoscale antibody (NanoAb) pipeline.

Contact details

Company: Joshua E. Phillipson | +972 8 930 2529 | [email protected]
Investor Relations: kenny green | +1 212 378 8040 | [email protected]

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect”, “believe”, “intend”, “plan”, “continue” , “may”, “will”, “anticipate” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this press release regarding strategy, future operations, future financial condition, future revenues, projected expenditures, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regardingng conference attendance, timing of future clinical trials, therapeutic and commercial potential of NanoAbs and execonclusion of a definitive amendment agreement with the EIB. These forward-looking statements reflect management’s current beliefs regarding certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the therapeutic and commercial potential of NanoAbs will not be realized; the risk of delay of preclinical and clinical data of the NanoAbs, if any; the risk that BiondVax and the EIB fail to reach an agreement on the restructuring of the European Investment Bank loan; the risk that BiondVax may not be able to obtain additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate lending under its financing agreement with BiondVax; risks related to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or not at all; time of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, as appropriate or required; the risk that the manufacturing facility cannot be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development will involve a long and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.


SOURCE BiondVax Pharmaceuticals Ltd.